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Abstract
Although imatinib is firmly established as an effective
therapy for newly diagnosed patients with chronic
myeloid leukemia (CML), the field continues to
advance on several fronts. In this minireview we cover
recent results of second generation tyrosine kinase
inhibitors in newly diagnosed patients, investigate the
state of strategies to discontinue therapy and report
on new small molecule inhibitors to tackle resistant
disease, focusing on agents that target the T315I
mutant of BCR-ABL. As a result of these advances,
standard of care in frontline therapy has started to
gravitate toward dasatinib and nilotinib, although
more observation is needed to fully support this.
Stopping therapy altogether remains a matter of
clinical trials, and more must be learned about the
mechanisms underlying the persistence of leukemic
cells with treatment. However, there is good news for
patients with the T315I mutation, as effective drugs
such as ponatinib are on their way to regulatory
approval. Despite these promising data, accelerated or
blastic phase disease remains a challenge, possibly
due to BCR-ABL-independent resistance.
Background
Chronic myeloid leukemia (CML) is a myeloproliferative
neoplasm caused by BCR-ABL, a chimeric gene gener-
ated as a result of a reciprocal translocation [t(9;22)(q34;
q11), cytogenetically visible as the Philadelphia chromo-
some (Ph)] that places sequences from the ABL gene
from chromosome 9 downstream of the BCR gene on
chromosome 22. The fact that tyrosine kinase activity of
BCR-ABL is conditio sine qua non for the protein’s ability
to transform cells led to the development of small mole-
cule tyrosine kinase inhibitors (TKIs) [1]. It is a little
more than ten years ago that the first TKI, imatinib, was
approved for the treatment of chronic myeloid leukemia
(CML) patients who had failed prior therapy with inter-
feron-a (IFN). Two years later, the International Rando-
mized Study of Interferon and STI571 (IRIS) study
demonstrated the superiority of imatinib over IFN/cytar-
abine (the standard drug therapy at the time), in newly
diagnosed chronic phase patients, and led to its approval
for first-line therapy [2]. Prior to the development of ima-
tinib, effective treatment for CML was limited to a min-
ority of patients. IFN-based regimens prolonged survival
compared to hydroxyurea, with induced durable
responses in 10-30% of patients [3,4]. However, this ben-
efit was largely limited to patients with low risk according
to Sokal and came at the expense of significant toxicity.
Allogeneic hematopoietic stem cell transplant in first
chronic phase from a matched related donor produced
five-year disease-free survival rates of approximately 50%.
However, transplant-related mortality and morbidity
were considerable and many patients were not eligible
due to co-morbidities or lack of a suitable donor [5]. All
this changed radically with the advent of imatinib. We
now have the luxury of asking questions that would have
seemed presumptuous just ten years ago, foremost
whether we can safely discontinue imatinib in patients
whose disease is consistently undetectable by RT-PCR.
The logical extension of this question is whether patients
who remain molecularly negative in the absence of ther-
apy are cured of their disease, and generally how we
should define cure in this context. Imatinib also changed
how CML treatment is monitored. The IRIS trial estab-
lished complete cytogenetic response (CCyR) and major
molecular response (MMR), defined as a 3-log reduction
of BCR-ABL transcripts compared to a standardized
baseline, as key milestones associated with excellent
long-term outcome, and provided a rationale for using
these surrogate endpoints in subsequent clinical trials [6].
Despite this unprecedented success, some clouds have
appeared in the sky of imatinib. Concerns first arose
when it became apparent that a substantial fraction of
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any medium, provided the original work is properly cited.the IRIS patients had left the study for a variety of rea-
sons, a fact that was not immediately appreciated from
Kaplan-Meyer or cumulative response graphics [7].
Thus at a follow-up of eight years, only 55% of patients
treated with first-line imatinib in the IRIS study were
still receiving imatinib, while the remainder had discon-
tinued therapy, mostly due to unsatisfactory therapeutic
effect or toxicity [8].
As a result of these concerns, the presentation of ‘patient
disposition’ at a given time of follow-up is increasingly
seen as mandatory complement to overall survival (OS)
and event free survival (EFS) estimates. Moreover, it has
become clear that the results of imatinib therapy are sig-
nificantly less favorable in the community setting. A report
from the Hammersmith Hospital defined imatinib failure
more broadly than the IRIS study as discontinuation of
drug for any reason, including toxicity. Additionally, the
lack of a major cytogenetic response was considered as
failure, in line with recommendations by the European
Leukemia Network (ELN) [9]. Using these criteria, EFS at
5 years was calculated at only 63% [10]. Even more alarm-
ing are results from a population-based study of CML
patients in Northwestern Britain that encompassed all
patients diagnosed with CML in a geographically defined
area over a 3.5 year period. At 24 months, only half of the
patients were in CCyR and receiving imatinib [11]. While
imatinib resistance can be caused by several mechanisms,
including mutations in the kinase domain of BCR-ABL, it
is likely that lack of adherence to medication is a major
underlying reason for these sobering data, possibly by pro-
moting the emergence of resistant clones through subopti-
mal, non-lethal target inhibition [12,13]. Perhaps it should
not come as a surprise that chronic oral cancer therapy is
subject to the same compliance limitations as other
chronic drug therapies, and this will not be different with
other oral agents [13]. Here we review three frontiers of
CML therapy: improvements in first-line treatment, the
therapeutic objective of disease eradication and novel
agents to overcome drug resistance.
The changing paradigm of frontline therapy for chronic
phase CML
Dasatinib and nilotinib are highly potent BCR-ABL inhibi-
tors that were initially approved for the treatment of
patients who had failed prior therapy, including imatinib.
Both are active against imatinib-resistant mutants of BCR-
ABL and induce durable cytogenetic responses in approxi-
mately 50-60% of chronic phase patients, while responses
in advanced phases tend to be transient. Both agents were
recently compared with imatinib in the frontline chronic
phase setting. The Dasatinib Versus Imatinib Study In
Treatment-naïve CML (DASISION) study tested dasatinib
100 mg daily versus imatinib 400 mg daily, whereas the
Evaluating Nilotinib Efficacy and Safety in Clinical Trials-
Newly Diagnosed Patients (ENESTnd) study compared
two doses of nilotinib (400 mg twice daily and 300 mg
twice daily) with imatinib 400 mg daily [14,15]. Both stu-
dies found the experimental arms superior in the primary
endpoint (DASISION: confirmed CCyR by 12 months;
ENESTnd: MMR at 12 months), and results were con-
firmed on a recent update (Table 1). Patients treated with
nilotinib had a significantly reduced risk of progression,
while no such difference was observed in the DASISION
study. Based on these results, both nilotinib and dasatinib
were approved for frontline therapy of newly diagnosed
patients in the US and in some European countries. A
third phase 3 trial (BELA): Bosutinib Efficacy and safety in
newly diagnosed chronic myeloid LeukemiA) tested bosu-
tinib, a second generation TKI not currently approved,
versus imatinib in newly diagnosed patients. Surprisingly,
this study failed to demonstrate superiority of the bosuti-
nib arm in the primary endpoint, the rate of CCyR at
12 months. It seems therefore unlikely that the drug will
be approved for frontline therapy [16]. There is suspicion
that the disappointing results may be due to frequent dose
interruptions for diarrhea, a common side effect of bosuti-
nib, which might have been manageable with more aggres-
sive supportive care. As many patients were treated in
smaller centers, this is a warning that ‘outsourcing’ of clin-
ical studies to less experienced centers can be problematic.
Should all newly diagnosed patients be treated with a
second generation inhibitor? Given the association
between CCyR on imatinib and EFS and OS, it is hard to
refute the logic of minimizing progression risk by redu-
cing leukemia burden faster and more profoundly. One
important factor is that the tolerability of the newer
agents is at least comparable to that of imatinib. How-
ever, differences in OS have yet to be observed, albeit
with limited follow-up. Another concern in both studies
is that approximately 20% of patients had dropped out
from the experimental arms for a variety of reasons.
Additionally, EFS on imatinib is excellent in patients with
low risk according to Sokal or Hasford score, suggesting
that these patients may be safely managed with the less
expensive drug, an issue that will become even more
important once generic imatinib becomes available (likely
in 2015). One would predict that the clinical importance
of accurate molecular prognostication tools, such as gene
expression profiling, will increase proportionately to the
price difference between alternative therapeutic options
[17].
Which parameters will guide the selection of dasatinib
or nilotinib in newly diagnosed patients? In the absence
of a direct comparison between the two agents, and in
view of their overall comparable efficacy, the selection of
therapy is directed primarily toward minimizing the side
effects. Both agents are generally well tolerated; however,
conditions such as a history of GI bleeding or congestive
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median age at diagnosis is 60 years. On the other hand,
convenience may favor dasatinib due to the once daily
dosing schedule and independence from meals, impor-
tant aspects for patients with an irregular life style.
Whether the different dosing regimens indeed translate
into differences in adherence has not yet been studied.
Eradicating the CML clone?
The most convincing argument for a switch to second
generation TKIs would be the ability to eventually discon-
tinue therapy in a larger fraction of patients. The French
Stop Imatinib (STIM) study enrolled 100 CML patients
who had been in complete molecular response (CMR:
consistently negative BCR-ABL PCR using an assay with a
sensitivity of 1:10
5) for a minimum of two years prior to
discontinuation of imatinib [18]. With a median follow-up
of 17 months, 54 patients had experienced a recurrence,
with the majority relapsing during the first six months.
The overall probability of maintaining a CMR at 12 months
was 43%, and in the sixty-nine patients followed for more
than 12 months, the recurrence-free survival was 41% and
38% at one and two years, respectively. Female sex, higher
Sokal risk score, and shorter duration of therapy were all
associated with recurrence, while previous treatment with
IFN did not affect relapse rates. Similar results were
reported in a smaller Australian study [19]. One can only
speculate about the eventual outcome of these trials. All
patients may eventually experience a recurrence, or there
may be a subset of patients who maintain CMR long-term.
Given that the sensitivity of any assay to detect residual
leukemia is eventually limited, we will never know whether
such patients are ‘cured’, implying that an operational defi-
nition of cure is required, perhaps as a risk of developing
clinical CML that is not different from the risk of the gen-
eral population. The hope is now that second generation
TKIs will allow for permanent discontinuation of therapy
in a larger proportion of patients. Indeed, the DASISION
and ENESTnd studies showed higher rates of CMR in the
experimental arms (Table 1). On the other hand, one
could argue that the overall rate of CMR is lower than
would be expected from the very rapid decline of leukemia
burden, suggesting that in most patients the residual
population of CML cells is beyond the reach of TKIs, con-
sistent with the observation that primitive CML cells
maintain viability despite TKI-induced inhibition of BCR-
ABL [20].
If CML stem cells are innately resistant to TKIs, can
they be targeted with drug combinations? The most pro-
mising results have been reported from the SPIRIT study,
which tested 400 mg and 600 mg imatinib daily vs. combi-
nations of 400 mg imatinib with pegylated IFN-a-2a or
cytarabine. At 12-months, the rates of MMR and CMR
were significantly higher in the imatinib/pegylated IFN-a-
2a arm compared to all other arms [21]. Similar results
were seen in the Nordic CML study, which used a com-
parable combination, but not in the German CML IV trial,
which used conventional IFN in combination with imati-
nib [22,23]. It is tempting to speculate that the type of IFN
is responsible for the discrepant results, highlighting the
fact that every detail matters. On the other hand, given
that no difference in EFS or OS has been observed thus far
in any of the studies, the ‘real world’ impact of these find-
ings remains to be seen with longer follow-up. Other
agents currently in early clinical testing in combination
with TKIs include inhibitors of the Hedgehog pathway,
inhibitors of authophagy, histone deacetylase inhibitors
and others.
New options for patients with drug resistance
Dasatinib and nilotinib are active in patients with imati-
nib failure. As with any other therapy for CML, responses
are generally durable in chronic phase, but only transient
in accelerated or blastic phase. While point mutations in
Table 1 Response rates in phase 3 studies comparing imatinib with nilotinib or dasatinib
DASISION ENESTnd
Median follow-up (months) 18 NR
Minimum follow-up (months) 16 24
Dasatinib 100 mg
QD
Imatinib 400 mg
QD
Nilotinib 300 mg
BID
Nilotinib 400 mg
BID
Imatinib 400 mg
QD
(N = 259) (N = 260) (N = 282) (N = 281) (N = 283)
Confirmed complete cytogenetic response by 18
mo (%)
78 70 NR NR NR
Major molecular response at any time (%) 57 41 71 67 44
Complete molecular response at any time (%) 13 7 26 21 10
Overall survival (%) 96.0 97.9 97.4 97.8 96.4
Progression-free survival (%) 94.9 93.7 98 97.7 95.2
Discontinued treatment (%) 19 20 26 22 33
Data are based on the update reported at the 2010 Annual Meeting of the American Society of Hematology in Orlando, FL. NR = not reported.
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mechanism of resistance, it has become increasingly clear
that resistance is more complex. This is supported by at
least two lines of evidence. Firstly, many patients with
resistance, particularly primary resistance in chronic
phase, do not have BCR-ABL kinase domain mutations
[24]. Secondly, with the exception of the pan-resistant
T315I mutant, there is only weak correlation between in
vitro sensitivity and in vivo response, indicating that
additional mechanisms must in part govern responses,
including mechanisms that are BCR-ABL-independent
[25,26]. It is likely that the true prevalence of BCR-ABL-
independent resistance will be known only when a TKI
with activity against all mutants of BCR-ABL, including
T315I, is available and widely used. Two agents have
emerged that might test this hypothesis. Ponatinib (for-
merly AP24534) is a multitargeted kinase inhibitor that is
active against all BCR-ABL mutants tested, including
T315I. In vitro mutagenesis screens failed to reveal any
new single mutation liability, in contrast to second-line
TKIs tested with the same experimental system [27]. In a
phase I study that included mostly patients with Ph-posi-
tive leukemia who had failed at least two TKIs, more
than 50% of patients in chronic phase attained CCyR.
Remarkably, the rate was close to 100% in patients with
the T315I mutation, transforming a prognostically unfa-
vorable biomarker into a predictor of favorable response
[28]. As always, responses in patients with advanced dis-
ease were less frequent, less profound and less stable.
Although the mechanisms underlying ponatinib resis-
tance have not been studied, it is possible that BCR-ABL-
independent resistance will become common. Alterna-
tively, as yet unidentified composite mutations may play
a role, either alone or in combination with conventional
mechanisms, such as drug efflux and BCR-ABL amplifi-
cation. A phase II study of ponatinib is currently ongoing
and may shed first light on this issue. Another mechanis-
tically different BCR-ABL kinase inhibitor is DCC-2036.
This compound binds to the switch pocket, an allosteric
site that controls the conformational changes that are
required for the kinase to ‘breath’, allowing for repeated
cycles of ATP and substrate interaction. Like Ponatinib,
DCC-2036 is active against a broad spectrum of kinase
domain mutants, including T315I, and mutagenesis
assays show near-complete suppression of resistant clone
outgrowth at high drug concentrations [29]. A phase I
study is currently recruiting, but results have not yet
been presented.
Conclusion
The landscape of CML management has changed consid-
erably since approval of imatinib. Long-term survival is a
reality for the majority of patients, and one could argue
that there would be much less demand for new therapies
if patients were more compliant or physicians were better
at managing side effects. In 2011 we have the privilege of
witnessing improvements to first-line therapy using sec-
ond generation TKIs, while third-line TKIs emerge as an
effective salvage for patients who fail nilotinib and dasati-
nib, including those with the T315I mutation. It is easy
to predict that the next quantum leap will be the ability
to discontinue therapy altogether. For now, this option is
limited to few selected patients, but the hope is that this
population will grow with frontline use of dasatinib or
nilotinib. However, some skepticism seems in order and
it is conceivable that for the majority of patients, disease
eradiation is beyond the reach of TKIs. Time will tell
whether combinations with other signal transduction
inhibitors or old-fashioned IFN might achieve this end
result.
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